Eimad Shotar 1 , Louis Meyblum 2 , Kevin Premat 2,3 , Stéphanie Lenck 2 , Vincent Degos 3,4 , Teodor Grand 2 , Jonathan Cortese 2 , Arnaud Pouvelle 2 , Geoffroy Pouliquen 2 , Samuel Mouyal 2 , Anne-Laure Boch 5 , Alexandre Carpentier 3,5 , Nader-Antoine Sourour 2 , Bertrand Mathon 3,5 , Frédéric Clarençon 2,3 . Show Affiliations »
Abstract
BACKGROUND: Embolization of the middle meningeal artery (MMA) has emerged as a potential treatment of chronic subdural hematomas (CSDHs). OBJECTIVE: To evaluate the impact on recurrence rate of postsurgical embolization of CSDH in patients with a higher than average risk of recurrence. METHODS: A monocentric retrospective study was performed on retrospectively collected data. From March 2018 to December 2019, embolization of the MMA was proposed as an adjunct postoperative treatment after burr-hole surgery in patients operated for a recurrent CSDH or a CSDH with an independent recurrence risk factor, including antiplatelet therapy, full anticoagulation therapy, coagulation disorder, hepatopathy, or chronic alcoholism. Patients who had undergone postoperative embolization were compared with a historic group of patients operated between March 2016 and March 2018, selected based on the same inclusion criteria. RESULTS: During the study period, 89 patients (with 74 unilateral and 15 bilateral CSDHs) were included and underwent an embolization procedure, leading to 91 out of a total of 104 MMA being embolized (88%). These were compared with 174 patients (138 unilateral and 36 bilateral CSDH) in the historic control group. One major procedure-related adverse event was registered. Four of the 89 patients (4%) required surgery for a CSDH recurrence in the embolization group, significantly less than the 24 of 174 patients (14%) in the control group (OR=0.28, 95% CI 0.07 to 0.86, p=0.02). CONCLUSIONS: Postsurgical embolization of the MMA may reduce the recurrence rate of CSDHs with a risk factor of recurrence. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
BACKGROUND: Embolization of the middle meningeal artery (MMA ) has emerged as a potential treatment of chronic subdural hematomas (CSDHs). OBJECTIVE: To evaluate the impact on recurrence rate of postsurgical embolization of CSDH in patients with a higher than average risk of recurrence. METHODS: A monocentric retrospective study was performed on retrospectively collected data. From March 2018 to December 2019, embolization of the MMA was proposed as an adjunct postoperative treatment after burr-hole surgery in patients operated for a recurrent CSDH or a CSDH with an independent recurrence risk factor, including antiplatelet therapy, full anticoagulation therapy, coagulation disorder , hepatopathy , or chronic alcoholism . Patients who had undergone postoperative embolization were compared with a historic group of patients operated between March 2016 and March 2018, selected based on the same inclusion criteria. RESULTS: During the study period, 89 patients (with 74 unilateral and 15 bilateral CSDHs) were included and underwent an embolization procedure, leading to 91 out of a total of 104 MMA being embolized (88%). These were compared with 174 patients (138 unilateral and 36 bilateral CSDH ) in the historic control group. One major procedure-related adverse event was registered. Four of the 89 patients (4%) required surgery for a CSDH recurrence in the embolization group, significantly less than the 24 of 174 patients (14%) in the control group (OR=0.28, 95% CI 0.07 to 0.86, p=0.02). CONCLUSIONS: Postsurgical embolization of the MMA may reduce the recurrence rate of CSDHs with a risk factor of recurrence. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Entities: Chemical
Disease
Gene
Species
Keywords:
chronic subdural hematoma; embolization; middle meningeal artery; recurrence
Mesh: See more »
Year: 2020
PMID: 32439812 DOI: 10.1136/neurintsurg-2020-016048
Source DB: PubMed Journal: J Neurointerv Surg ISSN: 1759-8478 Impact factor: 5.836